- Investopedia•2 days ago
Immunomedics sued venBio's board in a dispute concerning its $2 billion deal with Seattle Genetics.
- GlobeNewswire•2 days agoImmunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies
ORLANDO, Fla., Feb. 23, 2017-- Immunomedics, Inc., today reported a notable increase in potency when its novel bispecific antibodies that can redirect T cells, a type of immunoactive white blood cells, ...
- Business Wire•3 days ago
venBio Select Advisor LLC , the beneficial owner of approximately 10.5 million shares, or 9.9%, of Immunomedics, Inc. and its largest stockholder, today sent a letter to Immunomedics stockholders in connection with venBio’s nomination of four highly-qualified candidates – Scott Canute, Peter Barton Hutt, Dr.
IMMU : Summary for Immunomedics, Inc. - Yahoo Finance
Immunomedics, Inc. (IMMU)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.33 x 1000|
|Ask||5.36 x 1300|
|Day's Range||4.79 - 4.95|
|52 Week Range||1.95 - 5.89|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|